Xylazine (a sedative and analgesic approved only for veterinary use) has been designated by the US federal government as an emerging threat due to its increasing presence in fatal overdoses.
1 Xylazine-involved overdose deaths in the US rose from 102 in 2018 to 3468 in 2021,
2 and 99.1% of these deaths also involved fentanyl.
2 Xylazine-involved overdose deaths are primarily concentrated in the eastern US,
2 especially in the Northeast.
3 Nonetheless, it is less clear to what extent xylazine is involved in overdose deaths within individual states across the US, as xylazine is not uniformly included in every jurisdiction’s postmortem toxicology testing, and counts of xylazine-involved overdose deaths are not accessible via the Centers for Disease Control and Prevention (CDC)’s national mortality database. State-level data on xylazine-involved overdose deaths are currently limited in peer-reviewed publications, including analyses from individual states (Connecticut
4; West Virginia
5; Tennessee
6) and a CDC report
7 providing ranges (eg, 100 to 499 deaths) of fentanyl-xylazine–positive deaths for 31 states. In a 2022 publication,
8 data on xylazine-related overdose deaths were available for only 14 jurisdictions in the US (including cities, counties, and states).